Every 8-K that Apyx Medical Corporation (APYX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow APYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APYX filings page.
Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders on August 6, 2026. Stockholders elected five directors and ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 29,814,618 votes cast in favor.
Stockholders also approved a non-binding advisory resolution on executive compensation, receiving 21,458,554 votes in favor, and approved the Company’s 2026 Share Incentive Plan, which obtained 16,186,776 votes cast in favor, 2,755,882 votes against, and 3,276,000 abstentions.
Apyx Medical Corporation reported that on August 6, 2026 it issued a press release presenting its results of operations for the second quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states that this earnings information is furnished under Item 2.02 of the Exchange Act, rather than filed for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act reports unless specifically referenced. The report also identifies a Cover Page Interactive Data File, prepared using Inline XBRL, as Exhibit 104.
On July 24, 2026, Apyx Medical Corporation reported that its Board of Directors reconstituted the membership and chairs of its standing committees.
Following his appointment as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under applicable Nasdaq Global Select Market and SEC rules and that Mr. Waldman qualifies as an audit committee financial expert under SEC regulations.
Apyx Medical Corporation has appointed Board Chairman Stavros Vizirgianakis as Executive Chairman under a new letter agreement dated June 11, 2026. In this role, he will provide strategic leadership, governance oversight, support for corporate initiatives, investor engagement, and advice on capital markets and corporate development.
In connection with this appointment and in recognition of his service, the Board granted Mr. Vizirgianakis 450,000 restricted stock units under the 2023 Share Incentive Plan. Of these, 150,000 RSUs vest immediately on June 11, 2026, with two additional tranches of 150,000 RSUs each vesting monthly over 12-month periods starting on the first and second anniversaries of the grant date. He will not be an officer or "executive officer" of the company.
Apyx Medical Corporation filed an 8-K to highlight new clinical data supporting its minimally invasive technologies for treating cellulite and skin laxity. The study, published in Aesthetic Surgery Journal Open Forum, evaluated a single-session combination treatment using Avéli for targeted subcision and Renuvion for controlled helium plasma radiofrequency tightening.
The prospective investigator-initiated study treated 22 patients and reported progressive improvement over time, with visible reductions in cellulite and, in a subset of patients, increased collagen and elastin levels through 180 days after treatment. These results add to the company’s evidence base for its Renuvion and AYON body contouring platforms, which are already backed by more than 90 clinical documents.
Apyx Medical Corporation filed an 8-K to highlight a new retrospective, investigator-initiated clinical publication evaluating its Renuvion® technology used with liposuction. The 113-patient study in Plastic and Reconstructive Surgery – Global Open found that adding helium plasma radiofrequency (Renuvion) after liposuction was associated with higher patient-reported satisfaction with abdominal appearance and excess skin, lower abdominoplasty and surgical revision rates, and complication rates comparable to conventional power-assisted liposuction alone.
The company notes this study adds to a body of more than 90 clinical documents supporting Renuvion and J-Plasma®. It also reiterates that its AYON Body Contouring System™ is an FDA-cleared, surgeon-designed platform integrating fat removal, contouring and Renuvion-based tissue contraction, and that an additional 510(k) for AYON label expansion to include power liposuction was filed in October 2025.
Apyx Medical Corporation reported that it has received expanded FDA 510(k) clearance for its AYON Body Contouring System, adding a power liposuction capability. This advanced liposuction uses a reciprocating cannula designed to improve fat removal efficiency and reduce surgeon effort and operating room time.
The company plans a limited commercial launch of the new power liposuction function to work closely with early adopters, refine training, and optimize utilization before scaling broader commercialization. AYON is described as an all-in-one, surgeon-designed body contouring platform that integrates fat removal, contouring, tissue contraction, and electrosurgical capabilities.
Apyx Medical Corporation reported strong first quarter 2026 growth with higher revenue and narrower losses. Sales rose to $12.5 million from $9.4 million, led by Surgical Aesthetics revenue of $10.7 million, up 36.1% year over year, and OEM revenue of $1.8 million, up 13.8%.
Gross profit increased to $7.9 million with gross margin improving to 63.5%. Net loss attributable to stockholders improved to $2.1 million, or $0.05 per share, compared with a $4.2 million loss, or $0.10 per share, a year earlier. Adjusted EBITDA loss narrowed to $0.3 million from $2.4 million.
The company ended March 31, 2026 with $31.1 million in cash and cash equivalents and raised full‑year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, citing strong uptake of the AYON Body Contouring System and better‑than‑expected international demand.
Apyx Medical Corporation reported stronger results for the fourth quarter and full year 2025, helped by the U.S. launch of its AYON Body Contouring System. Fourth quarter revenue rose to $19.2 million from $14.2 million, with Surgical Aesthetics sales up 38.1% to about $16.7 million.
Net loss for the quarter narrowed to $1.3 million, or $0.03 per share, compared with $4.6 million, or $0.12 per share, and Adjusted EBITDA improved to a positive $0.7 million from a loss of $2.2 million. For 2025 overall, revenue increased 9.9% to $52.8 million, while net loss attributable to stockholders improved to $11.2 million from $23.5 million.
The company ended 2025 with $31.7 million in cash and cash equivalents and believes its cash can last through 2027. For 2026, it expects total revenue of $57.5 million to $58.5 million, driven by Surgical Aesthetics growth and partially offset by lower OEM revenue, as it continues scaling AYON in the U.S.
Apyx Medical Corporation reported that it has released preliminary revenue results for the fourth quarter and full year ended December 31, 2025. The company disclosed this information through a press release dated January 12, 2026, which is furnished as Exhibit 99.1. The report clarifies that these disclosures are provided under a results of operations and financial condition item and are furnished rather than filed under securities laws, which affects how they are treated for liability purposes.
Apyx Medical Corporation reported that its stockholders approved an amendment to its Certificate of Incorporation at the August 7, 2025 annual meeting to remove Article EIGHTH and replace it with the phrase “intentionally omitted.” On December 8, 2025, the company filed a Certificate of Amendment with the Delaware Secretary of State to put this change into effect, and the full text of the amendment is included as an exhibit.
Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to complete a public offering of its common stock. The Company issued 2,762,431 shares at an offering price of $3.62 per share and granted the underwriter an option to purchase up to an additional 414,365 shares. The offering closed on November 19, 2025, generating approximately $9.4 million in aggregate gross proceeds after a 6.0% underwriting discount and before expenses.
The Company plans to use the net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, potential acquisitions of complementary businesses, products or technologies, and repayment of indebtedness it may incur. The transaction was conducted under an existing Form S-3 shelf registration, and customary legal opinions and underwriting documents were filed as exhibits.
Apyx Medical Corporation furnished an 8-K announcing it issued a press release reporting results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, or incorporated by reference into Securities Act or Exchange Act filings, except as expressly set forth by specific reference.
Apyx Medical Corporation reported the outcomes of proposals submitted at its annual meeting. Stockholders elected five directors to serve on the board until the 2026 annual meeting, with each nominee receiving between 18.88 million and 19.11 million votes in favor and 6.77 million broker non-votes recorded in those tallies. Shareholders ratified RSM US LLP as the company’s independent registered public accounting firm by a vote of 25,930,634 in favor. A non-binding advisory vote on executive compensation passed with 18,963,101 votes for. A separate advisory vote on frequency favored a one-year option (9,205,086 votes). Stockholders also approved an amendment to delete the text of Article EIGHTH, with 19,047,016 votes for.